



2026 1H Presentation

**DELIVERING ON STRATEGY,
MOMENTUM AND VISIBILITY**



ASX: AHC | FEBRUARY 2026

CLAYTON ASTLES
CHIEF EXECUTIVE OFFICER

BRENDAN MAHER
CHIEF FINANCIAL OFFICER

For personal use only

1H-26 HIGHLIGHTS

MOMENTUM, STRUCTURAL TAILWINDS, FINANCIAL STRENGTH.

For personal use only



MOMENTUM AND LEVERAGE

1H-26 revenue of **\$48.2m (+30.7% pcp)** and EBITDA of **\$8.3m (+60.1% pcp)**, reflecting continued operating leverage and consistent execution.



STRUCTURAL GROWTH TAILWINDS

Global healthcare digitalisation projected* to **grow from US\$389b (2024) to US\$1.9t by 2031 (25.7% CAGR)**, driven by ageing populations and rising demand for safer, more efficient care.



GLOBAL SCALE

Operations across **6 countries**, supporting healthcare **installations in more than 50 countries** worldwide, with a global workforce of approximately 270 employees.




DIFFERENTIATED PLATFORM

IP-native nurse call platform with integrated RTLS and workflow applications, supporting improved outcomes and a **growing software and recurring revenue mix**.



BALANCE SHEET STRENGTH AND VISIBILITY

Debt-free; **\$15.2m cash** on balance sheet (1H-26); **\$47.2m** unfilled contract revenue (UCR)** provides visibility into future earnings.




1H-26 SCORECARD

DELIVERING ON STRATEGY, MOMENTUM ACROSS ALL METRICS


For personal use only

Revenue




Revenue increased 30.7% to \$48.2m, driven by the contribution and successful integration of acquisitions alongside continued organic growth, particularly in North America and Australia and New Zealand.

EBITDA




EBITDA increased 60.1% to \$8.3m, reflecting strong revenue growth and improving operating leverage, with scale benefits offsetting the increased cost base from acquired businesses and continued investment in R&D.

NPBT



Net profit before tax increased 62.1% to \$6.3m, highlighting the scalability of the Group's operating model as revenue growth continues to translate into accelerated profit growth.

EBITDA Margin



EBITDA margins continued to improve, demonstrating the benefits of scale, disciplined cost control, and the increasing contribution from higher margin acquired businesses.

Definitions: EBITDA = Earnings Before Interest, Tax, Depreciation & Amortisation; NPBT = Net Profit Before Tax; YoY = Year-over-Year; bp = basis points (1bp = 0.01%)

1H-26 OPERATING MOMENTUM

PROJECT TIMING, INTEGRATION AND OPERATING LEVERAGE

For personal use only

PROJECT TIMING

Austco's revenue reflects installation timing across regions and project milestones.

1H performance provides a solid operational base across key markets.

M&A EXECUTION AND INTEGRATION

Recent acquisitions are integrated and contributing as expected, strengthening scale and expanding capability across ANZ and North America.

OPERATING LEVERAGE

Revenue growth translated into stronger EBITDA and NPBT growth, reflecting scalability of the business model and consistent cost management.

HEALTHCARE MEGATRENDS

GLOBAL FORCES DRIVING DEMAND FOR SAFER, SMARTER CARE

Ageing Demographic


727m (2025) → 1.5b aged 65+ by 2050 (3% CAGR)*
Increasing demand for care.

Healthcare Digitisation

US\$389b (2024) → US\$1.9t by 2031 (26% CAGR)**
Data & analytics.

Regulatory Demands

US\$2.8b (2023) → US\$8.1b by 2032 (13% CAGR)***
Compliance focus



For personal use only

AUSTCO AT A GLANCE

"A GLOBAL HEALTHCARE TECHNOLOGY PARTNER"

*"TRUSTED BY LEADING
HOSPITALS AND AGED
CARE PROVIDERS ACROSS
5 CONTINENTS."*

TRUSTED EXPERTISE

"Supporting international healthcare installations in 50 countries worldwide through employees and trusted partners globally."

GLOBAL FOOTPRINT

"International presence with 270 employees across 6 countries: Australia (HQ), USA (Product & Development), New Zealand, Singapore, Canada, & UK."

DEMAND-ALIGNED SOLUTIONS

"Comprehensive platform portfolio spanning communication (Tacera), workflow optimisation (Pulse), asset tracking (RTLS)."

STRONG FINANCIAL FOUNDATION

"Revenue +31% HoH (\$48.2m), EBITDA margin 17.1%, debt-free balance sheet with \$15.2m cash."

For personal use only

Notes: Definitions: RTLS = Real-Time Location Systems; SMA = Software Maintenance Agreement

AUSTCO SOLUTIONS IN ACTION

A JOURNEY OF TECHNOLOGY INNOVATION, FROM CONCEPT TO CARE

For personal use only




DEVICES & DATA

Patient devices, in-room devices, real-time location components, integrated clinical systems



TACERA SOFTWARE & CLINICAL INTELLIGENCE

Alarm handling, RTLS location parsing, call routing, audio comms, information from third-party systems



ALERTS, NOTIFICATIONS, MOBILE APPS, TOUCHSCREENS, INFORMATION DISPLAY



SECURITY, CCTV, ACCESS CONTROL INSTALLATIONS & INTEGRATION

Installation, configuration, Integration, maintenance

CLINICAL SYSTEMS

LOW VOLTAGE

Notes: Definitions: RTLS = Real-Time Location Systems;

INFORMATION BOARDS

Display important information where staff need it.

Supporting workflow visibility and real-time clinical coordination.

For personal use only

4:21 PM WEDNESDAY 23 APR 100%

Good Morning, Margaret

Get Help My Care Team My Stay

Water Bathroom Assistance Order Food

Help with TV / Entertainment Call My Nurse

Rate your pain level

Have concerns?

I have questions for my care team

When I call for help, it takes a long time for people to arrive

LOCATION	PATIENT	STATUSES	CARE TEAM	ASSIST	DIET	LOS	DISCHARGE	PT	OT	SW	SP	RED	ALERT
Room 1	Markina, G. 48Y	STAY	Miller, S. Tuloscoops, M. Sotomata, S. Eldenoc, H.	Cardiac, Purved	Reg	6	Today 20 Jul 24						
Room 2	Moody, A. 68Y	STAY	Miller, S. Tuloscoops, M. Sotomata, S. Patel, I.	Cardiac, Fiber	Reg	12	Overdue 20 Jul 24						
Room 3	Lakshmi, N. 78Y	STAY	Miller, S. Tuloscoops, M. Sotomata, S. Patel, I.	Regular	Reg	3	Tomorrow 20 Jul 24						
Room 4	Doveller, M. 67Y	STAY	Schroeder, R. Tsampis, E. Sotomata, S. Eldenoc, H.	Regular	Reg	2	30 Jul 24						
Room 5	Bartley, M. 62Y	STAY	Miller, S. Tuloscoops, M. Sotomata, S. Patel, I.		Reg	14	30 Jul 24						
Room 6	Latta, Y. 72Y	STAY	Ratched, N. Diaz, A. Hgater, A. House, G.	Cardiac, Soft	Reg	3	Tomorrow 20 Jul 24						
Room 7	Wick, J. 64Y	STAY	Ratched, N. Diaz, A. Hgater, A. House, G.		Reg	1	Today 20 Jul 24						
Room 8	McCullough, F. 72Y	STAY	Ratched, N. Diaz, A. Hgater, A. House, G.		Reg	9	04 Aug 24						
Room 9	Falundunberg, B. 80Y	STAY	Schroeder, R. Tsampis, E. Sotomata, S. Schelder, R.		Reg	3	Today 20 Jul 24						
Room 10	Diester, A. 65Y	STAY	Cumberbatch, B. Sorrentino, M. Boginskaya, S. House, G.	Low salt	Reg	6	Today 20 Jul 24						
Room 11	Bogstrand, A. 65Y	STAY	Cumberbatch, B. Sorrentino, M. Boginskaya, S. House, G.		Reg	1	21 Jul 24						
Room 12	Lofaringen, A. 64Y	STAY	Schroeder, R. Tsampis, E. Sotomata, S. Patel, I.		Reg	1	29 Jul 24						
Room 13	Longenman, J. 84Y	STAY	Cumberbatch, B. Sorrentino, M. Boginskaya, S. House, G.		Reg	2	02 Aug 24						
Room 14	Herbalicious, S. 85Y	STAY	Schroeder, R. Tsampis, E. Sotomata, S. Patel, I.		Reg	3	Tomorrow 20 Jul 24						
Room 15	Mitsunobu, S. 64Y	STAY	Cumberbatch, B. Sorrentino, M. Boginskaya, S. House, G.	Cardiac	Reg	3	Today 20 Jul 24						
Room 16	Beckman, V. 72Y	STAY	Cumberbatch, B. Sorrentino, M. Boginskaya, S. House, G.		Reg	19	02 Aug 24						
Room 17	Gattinger, K. 72Y	STAY	Cumberbatch, B. Sorrentino, M. Boginskaya, S. House, G.		Reg	4	Overdue 20 Jul 24						
Room 18	McIntosh, F. 81Y	STAY	Schroeder, R. Tsampis, E. Sotomata, S. Patel, I.		Reg	9	01 Aug 24						
Room 19	Nam, A. 78Y	STAY	Schroeder, R. Tsampis, E. Sotomata, S. Patel, I.		Reg	6	02 Aug 24						
Room 20	Zarandany, Z. 75Y	STAY	Ratched, N. Diaz, A. Hgater, A. House, G.		Reg	8	Today 20 Jul 24						

Hospital Moving Care Ahead

CARDIOLOGY | ROOMS 1-20

TUESDAY FEB 18, 2025 3:1

DALLAS 312-963-0714 FREEWIFI

MEDSURG . ROOM 17

NICKNAME: Margie
DOB: 25/Aug/1939
LANGUAGE: English

Good Morning, Margaret

CARE TEAM

- Elaine A. RN
- Jia M. Patient Care Tech
- Yisang 'Ethan' W. Attending Physician

NEXT VISIT

- Jia M. 04:00 PM

MOBILITY

You require assistance when walking. Please call a staff member.

COMFORT GOALS

Goal: 3 Current: 6

NEXT PAIN ASSESSMENT

03:40 PM Elaine A. RN

DAILY SCHEDULE

- 09:00 X-ray (Radiology RL-2)
- 12:00 Consult, Dr. Heiling
- 14:00 Surgery (OR-4)

DISCHARGE PLAN

- PT: 4 sessions
- Walk 50ft unassisted
- Schedule in-home PT
- Final consult: Dr. Hunt

Expected Discharge Date: 24 Feb 2025


Let us know how we're doing

Access room controls

Hospital Moving Care Ahead


TUESDAY FEB 18, 2025 3:15 PM

ENTERPRISE PRODUCTS




OPERATIONAL INSIGHTS

AI-Informed
Call Volume & Staffing
Unusual Call Patterns
Automatic Workflow Assignment



FALL DETECTION, MOVEMENT

Radar or camera-based
Over time, can predict resident
needs



SYSTEM READINESS

Network,
Servers,
Device Faults,
Database Storage

Driving software penetration and recurring revenue expansion.

AI-ENABLED HEALTHCARE

EMBEDDING INTELLIGENCE ACROSS THE AUSTCO PLATFORM

For personal use only



Predictive Clinical Intelligence

Leveraging call data and RTLS positioning to predict patient needs before escalation – fall risk scoring, call anomaly detection, and deterioration early warning.



Intelligent Workflow Optimisation

Extending automatic workflow assignment with AI-powered staff routing based on acuity, workload, proximity via RTLS, and skill matching – reducing response times.



Operational Analytics & Decision Support

Transforming system data into actionable insights for hospital administrators – response time analysis, staffing adequacy, and compliance readiness dashboards.



Predictive Maintenance & System Health

AI monitoring of installed hardware and network infrastructure globally to flag device issues before downtime – strengthening SMA value and system uptime.

Strategic Alignment: AI will enhance Austco's existing Tacera, Pulse, and RTLS platforms – deepening platform stickiness, expanding recurring software revenue, and widening competitive differentiation.

AUSTCO'S VALUE PROPOSITION

ENABLING SAFER, SMARTER AND MORE EFFICIENT CARE

Improve Clinical Outcomes

Supports patient safety, workflow visibility and real-time response coordination.

Enhance Operational Efficiency

Reduces manual processes, improves staff productivity and enables better resource planning.

Scalable, Integrated Platform

Embedded within hospital systems, supporting long-term recurring relationships and expanding software contribution.

For personal use only

GROUP FINANCIAL SUMMARY

STRONG TOP-LINE GROWTH WITH EXPANDING MARGINS

	1H-26	1H-25	Variance
Revenue from customers	48,236	36,909	30.7%
Materials and Direct labour	(23,066)	(18,066)	27.6%
Gross Profit	25,170	18,843	33.6%
Gross Profit %	52.2%	51.1%	
Overhead Expenses	(16,914)	(13,680)	23.6%
EBITDA	8,256	5,163	60.1%
Net Interest/(expense)	(111)	62	
D&A	(1,894)	(1,349)	40.4%
Contingent Consideration	21	-	
Profit before tax	6,272	3,876	62.1%
Tax (expense)/credit	(1,535)	(945)	63.3%
Non Controlling interests	(12)	-	
Profit after Tax	4,737	2,931	61.7%

Gross profit increased 33.6% to \$25.2 million, with gross margin improving to 52.2%, reflecting scale benefits and operational efficiency execution despite the inclusion of lower margin acquired businesses.

Overhead expenses increased 23.6% to \$16.9 million, primarily reflecting the inclusion of acquired businesses, while growing at a lower rate than revenue.

EBITDA increased 60.1% to \$8.3 million, demonstrating strong operating leverage as revenue growth translated into accelerated earnings growth.

Profit before tax increased 62.1% to \$6.3 million, highlighting the underlying operating leverage of the Group's business model.

Tax and NPAT


Profit after tax **increased 61.7% to \$4.7 million**, reflecting higher underlying profitability and a normalised tax expense in the period.

For personal use only

GEOGRAPHIC REVENUE MIX

DIVERSIFIED GLOBAL FOOTPRINT DRIVING BROAD-BASED GROWTH

For personal use only



ANZ revenue increased 57% to \$26.9 million, driven primarily by contributions from recent acquisitions, including G&S Technologies and Onix*, as well as modest organic growth. As a result, ANZ represented approximately 56% of Group revenue for the period.

North America rose 38% to \$15.4 million, reflecting strong organic growth and continued demand, and represented approximately 32% of Group revenue.

Asia revenue down to \$3.9 million, due to the timing of project installations relative to a strong prior comparative period, and accounted for approximately 8% of Group revenue.


Europe was \$2.1 million, broadly stable year on year, with foreign exchange movements affecting the reported result, and accounted for approximately 4% of Group revenue.

Notes: *G&S Technologies (New Zealand): ASX release, May 2025 ([Link](#));
Definitions: ANZ = Australia & New Zealand

EBITDA EXPANSION – GEOGRAPHICAL SCALE

OPERATING LEVERAGE EVIDENT ACROSS KEY REGIONS

For personal use only



Group EBITDA rose 60% to \$8.3m, with EBITDA margins improving from 14.0% in 1H-25 to 17.1% in 1H-26.

Australia and New Zealand EBITDA increased 181% to \$6.3 million, reflecting contributions from acquired businesses and improved operating leverage. The region remains the largest contributor to Group EBITDA.

North America EBITDA increased to \$3.1 million, reflecting strong organic revenue growth and improved operating performance from a lower prior base.

Asia EBITDA down to \$1.1 million, reflecting lower revenue in the period due to the timing of project installations, which followed a strong prior comparative period.



Europe's EBITDA was \$0.3 million, broadly consistent with revenue movements and impacted by regional mix and foreign exchange.

Notes: *Group EBITDA is post eliminations (Inter-Company & Corporate) of \$0.475mn in 1H-25 & \$2.626mn in 1H-26, all geographic data is pre-eliminations & margins based by region on Revenue - external (see Note 5 "Segment Reporting" of Annual Report for data and notes- [Link](#))
 Definitions: EBITDA = Earnings Before Interest, Tax, Depreciation & Amortisation; ANZ = Australia & New Zealand

UNFILLED CONTRACTED REVENUE

VISIBILITY INTO FUTURE EARNINGS

For personal use only




Notes: *As at 16 February 2026
Definitions: SMA = Software Maintenance Agreement; ANZ = Australia & New Zealand

CASH FLOW AND CAPITAL ALLOCATION

PRUDENT CAPITAL DEPLOYMENT AND BALANCE SHEET STRENGTH

OPERATING CASH FLOW FUNDING M&A



Cash **\$14,483k** **\$9,187k** **-\$1,510k** **-\$6,020k** **-\$910k** **\$15,230k**

- **Operating cash flow of \$9.2 million** was broadly aligned with EBITDA, reflecting continued strong cash conversion and disciplined working capital management.
- **Cash outflows** in the period were primarily due to acquisition payments of \$6.0 million, with an additional \$1.1 million in R&D and modest capital expenditures of \$0.5 million, supporting ongoing investment in the business.
- Despite these outflows, the **Group generated a positive net cash flow of \$1.0 million** for the half, ending the period with \$15.2 million in cash and no debt.
- **The balance sheet continues to strengthen**, providing flexibility to fund reinvestment, innovation, and selective M&A from internal cash generation.

M&A SCORECARD

STRENGTHENING CAPABILITY, DELIVERING INTEGRATION, DISCIPLINED PIPELINE

STRENGTHENING CAPABILITY AND SCALE

Recent acquisitions* have expanded the Group's regional footprint, enhanced product capability and strengthened customer relationships, especially across ANZ and North America.

INTEGRATION AND PERFORMANCE

Acquired businesses are integrated into Group operations and contributing in line with expectations, supporting revenue growth and operating leverage.

SELECTIVE AND ACTIVE M&A PIPELINE

The Group continues to evaluate strategic opportunities aligned with its capability and geographic priorities, maintaining a measured approach to capital allocation.


For personal use only

STRATEGY & OUTLOOK

CLEAR PRIORITIES FOR SUSTAINABLE GROWTH AND SCALE

Continuous Innovation

Ongoing investment in product and platform capability to deepen integration and long-term customer value.



Enhance Margin Profile

Drive operating leverage through deployment efficiency and scale benefits across regions.




Deepen Market Presence

Strengthen regional execution and customer relationships across core markets, reinforcing Austco's position as a trusted healthcare technology partner.



Expand Recurring Revenue Base

Increase software and service penetration within the installed base, supporting greater revenue visibility and customer lifetime value.



Selective and Value-Aligned M&A

Evaluate strategic acquisition opportunities aligned with capability, geography and capital discipline, strengthening scale without compromising balance sheet strength.



Outlook

Maintain focus on execution, balance sheet strength and long-term value creation within a dynamic healthcare funding environment.



For personal use only

IMPORTANT INFORMATION & DISCLAIMER

This presentation was prepared by Austco Healthcare Limited and was authorised for release by the Board of the Company.

This presentation does not constitute an offer, invitation or recommendation for the sale or purchase of any securities in any jurisdiction.

References to, and the explanation of, legislation and regulatory issues in this Publication are indicative only and should not be relied on. They do not purport to summarise all relevant legislation and regulatory issues or to be a full explanation of any particular matter.

Past Performance

Past performance information given in this presentation is given for illustrative purposes and should not be relied upon as an indication of future performance.

Forward Looking Statements

The information contained herein involves elements of subjective judgment and analysis and may be identified by words such as 'may', 'could', 'believes', 'expects', 'intends' or other words that involve risk and uncertainty (collectively, forward looking statements). Any forward looking statements expressed in this Publication are subject to change without notice. They do not constitute, and should not be regarded as, a representation that the relevant results will actually be achieved or that the underlying assumptions upon which forward looking statements may be based are valid or reasonable. Actual results may vary from the forward looking statements and such variations may be material.

Other Information

All financial amounts contained in this presentation are expressed in Australian currency unless otherwise stated. Any discrepancies between totals and sums and components in tables contained in this presentation are due to rounding.

Disclaimer

Other than to the extent required by law, neither Austco nor any of their respective affiliates, associates, shareholders, directors, officers, employees, agents, representatives and advisers (the Austco Parties) make any representation or warranty (express or implied) as to, and assume responsibility or liability for, the authenticity, origin, validity, accuracy or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or in any accompanying, previous or subsequent material or presentation in connection with the subject matter of this presentation.

Without limiting the foregoing, none of the Austco Healthcare Limited or its related entities:

- makes or purports to make any statement or representation (including, but not limited to, any representation with respect to any forward-looking statement) contained in this presentation;
- is responsible for the contents of this presentation;
- has verified the accuracy or completeness of this presentation; or is liable in any way for any misstatement in, or errors in or omission from, this presentation or in any accompanying, previous or subsequent material or presentation in connection with the subject matter of this presentation, except and then only to the extent required by law.

United States

In particular, this presentation is not an offer of securities for sale in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the United States Securities Act of 1933 (the Securities Act)). Austco, its affiliates and related bodies corporate are not and will not be registering any securities under the Securities Act or the securities laws of any state of the United States or any other jurisdiction other than the Commonwealth of Australia.

This document has been prepared for publication in Australia and may not be released or distributed in the United States or to U.S. persons. Failure to comply with this directive may result in a violation of the Securities Act and/or another applicable law of the United States or another jurisdiction.

For personal use only



Austco



CONTACT

MATTHEW PEARSON

INVESTOR RELATIONS
INVESTORS@AUSTCO.COM
AUST: +61 432 065 797